EIKN Financials

Income Statement
MetricQ2 2026Q1 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
93.4M
+6.9%
87.3M
R&D
75.5M
+7.7%
70.0M
SG&A
17.9M
+3.7%
17.3M
Operating Income
-93394000
-6.9%
-87338000
EBITDA
-88265000
-7.5%
-82124000
Net Income
-88409000
-6.6%
-82958000
EPS (Basic)
$-1.63
+33.7%
$-2.46
EPS (Diluted)
$-1.63
+33.7%
$-2.46
Shares (Diluted)
54.1M
+60.7%
33.7M
Eikon Therapeutics (EIKN) โ€” Financials